SE431821B - Lagringsstabilt, prostaglandininnehallande medicinskt preparat - Google Patents

Lagringsstabilt, prostaglandininnehallande medicinskt preparat

Info

Publication number: SE431821B
Authority: SE; Sweden
Prior art keywords: prostaglandin; preparation; water; polymer; gel
Prior art date: 1979-01-29

Application number

SE7900737A

Other languages

English (en)

Swedish (sv)

Other versions

SE7900737L (sv

Inventor

J A O Johansson

U I Ulmsten

Original Assignee

Perstorp Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-01-29

Filing date

1979-01-29

Publication date

1984-03-05

1979-01-29 Application filed by Perstorp Ab filed Critical Perstorp Ab

1979-01-29 Priority to SE7900737A priority Critical patent/SE431821B/sv

1979-12-17 Priority to SE7910354A priority patent/SE442167B/sv

1980-01-14 Priority to GB8001176A priority patent/GB2041220B/en

1980-01-16 Priority to US06/112,563 priority patent/US4352790A/en

1980-01-16 Priority to DE19803001454 priority patent/DE3001454A1/de

1980-01-18 Priority to JP519880A priority patent/JPS55102512A/ja

1980-01-23 Priority to NL8000426A priority patent/NL190693C/xx

1980-01-25 Priority to NO800186A priority patent/NO153520C/no

1980-01-25 Priority to BE0/199113A priority patent/BE881351A/fr

1980-01-28 Priority to DK033580A priority patent/DK160739C/da

1980-01-28 Priority to FR8001797A priority patent/FR2447191A1/fr

1980-07-30 Publication of SE7900737L publication Critical patent/SE7900737L/

1984-03-05 Publication of SE431821B publication Critical patent/SE431821B/sv

1986-07-03 Priority to DK316186A priority patent/DK160740C/da

Links

238000002360 preparation method Methods 0.000 title claims abstract description 39
238000003860 storage Methods 0.000 title description 6
150000003180 prostaglandins Chemical class 0.000 claims abstract description 38
229920000642 polymer Polymers 0.000 claims abstract description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
230000008961 swelling Effects 0.000 claims abstract description 12
239000002245 particle Substances 0.000 claims abstract description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
239000007788 liquid Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 10
238000009792 diffusion process Methods 0.000 claims description 6
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 5
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
239000004375 Dextrin Substances 0.000 claims description 4
229920001353 Dextrin Polymers 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 4
235000014633 carbohydrates Nutrition 0.000 claims description 4
235000019425 dextrin Nutrition 0.000 claims description 4
229920002307 Dextran Polymers 0.000 claims description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
229920001202 Inulin Polymers 0.000 claims description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
229920002472 Starch Polymers 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
230000001588 bifunctional effect Effects 0.000 claims description 2
238000004132 cross linking Methods 0.000 claims description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
229940029339 inulin Drugs 0.000 claims description 2
235000019698 starch Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims 1
239000001913 cellulose Substances 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 6
210000003679 cervix uteri Anatomy 0.000 description 5
239000000654 additive Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
206010000210 abortion Diseases 0.000 description 3
231100000176 abortion Toxicity 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229960002986 dinoprostone Drugs 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
230000035800 maturation Effects 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000320 mechanical mixture Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000035802 rapid maturation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000007966 viscous suspension Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SE7900737A 1979-01-29 1979-01-29 Lagringsstabilt, prostaglandininnehallande medicinskt preparat SE431821B (sv)

Priority Applications (12)

Application Number	Priority Date	Filing Date	Title
SE7900737A SE431821B (sv)	1979-01-29	1979-01-29	Lagringsstabilt, prostaglandininnehallande medicinskt preparat
SE7910354A SE442167B (sv)	1979-01-29	1979-12-17	Lagringsstabilt prostaglandin innehallande medicinskt preparat
GB8001176A GB2041220B (en)	1979-01-29	1980-01-14	Medical preparations containing prostaglandins
US06/112,563 US4352790A (en)	1979-01-29	1980-01-16	Medical preparation containing prostaglandin
DE19803001454 DE3001454A1 (de)	1979-01-29	1980-01-16	Stabiles, prostaglandin-haltiges arzneimittel
JP519880A JPS55102512A (en)	1979-01-29	1980-01-18	Blend and its administration
NL8000426A NL190693C (nl)	1979-01-29	1980-01-23	Stabiel, prostaglandine bevattend, farmaceutisch preparaat.
NO800186A NO153520C (no)	1979-01-29	1980-01-25	Fremgangsm¨te til fremstilling av et stabilt preparat inne holdende prostaglandin.
BE0/199113A BE881351A (fr)	1979-01-29	1980-01-25	Preparation medicale
DK033580A DK160739C (da)	1979-01-29	1980-01-28	Fremgangsmaade til fremstilling af et stabilt prostaglandinindeholdende praeparat til laegemiddelanvendelse
FR8001797A FR2447191A1 (fr)	1979-01-29	1980-01-28	Preparation medicale contenant de la prostaglandine et son utilisation pour application intravaginale et intracervicale
DK316186A DK160740C (da)	1979-01-29	1986-07-03	Stabilt prostaglandin-indeholdende praeparat til anvendelse som abortfremkaldende middel

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE7900737A SE431821B (sv)	1979-01-29	1979-01-29	Lagringsstabilt, prostaglandininnehallande medicinskt preparat

Publications (2)

Publication Number	Publication Date
SE7900737L SE7900737L (sv)	1980-07-30
SE431821B true SE431821B (sv)	1984-03-05

Family

ID=20337129

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SE7900737A SE431821B (sv)	1979-01-29	1979-01-29	Lagringsstabilt, prostaglandininnehallande medicinskt preparat
SE7910354A SE442167B (sv)	1979-01-29	1979-12-17	Lagringsstabilt prostaglandin innehallande medicinskt preparat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SE7910354A SE442167B (sv)	1979-01-29	1979-12-17	Lagringsstabilt prostaglandin innehallande medicinskt preparat

Country Status (10)

Country	Link
US (1)	US4352790A (da)
JP (1)	JPS55102512A (da)
BE (1)	BE881351A (da)
DE (1)	DE3001454A1 (da)
DK (2)	DK160739C (da)
FR (1)	FR2447191A1 (da)
GB (1)	GB2041220B (da)
NL (1)	NL190693C (da)
NO (1)	NO153520C (da)
SE (2)	SE431821B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0323530B2 (da) *	1979-03-21	1991-03-29	Nat Res Dev
US5079009A (en) *	1979-03-21	1992-01-07	National Research Development Corporation	Controlled release compositions including polyethylene oxide with urethane cross-linking
IT1131833B (it) *	1980-06-20	1986-06-25	Crinos Industria Farmaco	Eccipienti per sostanze spermicide
ZA831186B (en) *	1982-03-22	1983-11-30	Upjohn Ltd	Gelled pge2/triacetin solutions
AU546872B2 (en) *	1982-06-16	1985-09-26	Unilever Plc	Skin treatment compositions containing a fatty acid or ester
US4675182A (en) *	1983-02-12	1987-06-23	Bayer Aktiengesellschaft	Complexes of prostaglandins
DE3307816A1 (de) *	1983-03-02	1984-09-06	Schering AG, 1000 Berlin und 4709 Bergkamen	Prostaglandin-haltiges pharmazeutisches praeparat und seine herstellung
GB8403360D0 (en) *	1984-02-08	1984-03-14	Erba Farmitalia	Pharmaceutical compositions
DE3428264A1 (de) *	1984-07-27	1986-03-06	Schering Ag	Gelhaltige pharmazeutische zubereitungen
IE59361B1 (en) *	1986-01-24	1994-02-09	Akzo Nv	Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
JP2590358B2 (ja) *	1988-03-01	1997-03-12	正雄五十嵐	子宮内膜症治療用の子宮内又は膣内投与製剤
JPH03220201A (ja) *	1988-11-18	1991-09-27	Eisai Co Ltd	プロスタグランジン類と多糖類の結合体
CH678697A5 (da) *	1989-04-03	1991-10-31	Warner Lambert Co
AU664719B2 (en) *	1991-11-08	1995-11-30	Green Cross Corporation, The	Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
US6946442B2 (en) *	1994-11-30	2005-09-20	Asif Syed Ahmed	Method of hastening cervical ripening
CA2222811C (en) *	1995-06-01	2008-09-30	G.D. Searle & Co.	Stabilized solid dispersions of misoprostol
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
KR20010021625A (ko)	1997-07-09	2001-03-15	추후보정	개선된 남성발기 기능장애 치료방법 및 그 조성물
FR2766709B1 (fr) *	1997-07-31	2000-04-07	Dominique Cingotti	Procede pour la preparation d'un extrait de principes actifs sous forme de microgranules a base de fibres alimentaires entierement solubles destines a differentes formes galeniques
US6031002A (en) *	1998-05-01	2000-02-29	Michael Ebert	Method for enhancing female sexual response and a composition therefor
US5891915A (en) *	1998-05-01	1999-04-06	Wysor; Michael S.	Method for enhancing female sexual response and an ointment therefor
US20070191320A1 (en) *	1998-12-10	2007-08-16	Nexmed Holdings, Inc.	Methods of treatment for female sexual arousal disorder
US6486207B2 (en)	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en)	1998-12-10	2004-11-30	Nexmed (Holdings) , Inc.	Compositions and methods for amelioration of human female sexual dysfunction
GR1004266B (el) *	2001-04-30	2003-06-18	Ηλιας Κ. Παπαδοπουλος	Φαρμακευτικο παρασκευασμα για την διαγνωση και θεραπεια της στυτικης δυσλειτουργιας
US20050181030A1 (en) *	2003-01-03	2005-08-18	Mo Y. J.	Topical stabilized prostaglandin E compound dosage forms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3948254A (en) *	1971-11-08	1976-04-06	Alza Corporation	Novel drug delivery device
US3875300A (en) *	1972-12-18	1975-04-01	Ortho Pharma Corp	Composition for sustained release of a medicament and method of using same
US3888975A (en) *	1972-12-27	1975-06-10	Alza Corp	Erodible intrauterine device
US4036954A (en) *	1973-11-02	1977-07-19	Yamanouchi Pharmaceutical Co., Ltd.	Stable prostaglandin E group-containing formulation
AR205997A1 (es)	1973-11-21	1976-06-23	American Cyanamid Co	Resina de poliester normalmente solida biodegradable e hidrolizable
CH616694A5 (en) *	1974-06-27	1980-04-15	Ciba Geigy Ag	Process for the preparation of crosslinked, water-insoluble, hydrophilic copolymers
US4107288A (en)	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5256148A (en) *	1975-10-16	1977-05-09	Agency Of Ind Science & Technol	Process for preparing active substances having improved
GB1554783A (en)	1976-01-05	1979-10-31	Population Res Inc	Pharmaceutical compositions for use in the permanent sterilization of female animals
US4145555A (en) *	1976-03-12	1979-03-20	Ono Pharmaceutical Company	Δ3 -Prostaglandin analogs
GB1551620A (en) *	1976-12-13	1979-08-30	Ici Ltd	Delivery means for biologically active agents

1979
- 1979-01-29 SE SE7900737A patent/SE431821B/sv not_active IP Right Cessation
- 1979-12-17 SE SE7910354A patent/SE442167B/sv not_active IP Right Cessation
1980
- 1980-01-14 GB GB8001176A patent/GB2041220B/en not_active Expired
- 1980-01-16 DE DE19803001454 patent/DE3001454A1/de active Granted
- 1980-01-16 US US06/112,563 patent/US4352790A/en not_active Expired - Lifetime
- 1980-01-18 JP JP519880A patent/JPS55102512A/ja active Granted
- 1980-01-23 NL NL8000426A patent/NL190693C/xx not_active IP Right Cessation
- 1980-01-25 NO NO800186A patent/NO153520C/no unknown
- 1980-01-25 BE BE0/199113A patent/BE881351A/fr not_active IP Right Cessation
- 1980-01-28 FR FR8001797A patent/FR2447191A1/fr active Granted
- 1980-01-28 DK DK033580A patent/DK160739C/da not_active IP Right Cessation
1986
- 1986-07-03 DK DK316186A patent/DK160740C/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3001454A1 (de)	1980-08-07
DK316186D0 (da)	1986-07-03
DK160740B (da)	1991-04-15
US4352790A (en)	1982-10-05
DK160739C (da)	1991-09-30
SE442167B (sv)	1985-12-09
NO800186L (no)	1980-07-30
FR2447191B1 (da)	1983-07-22
SE7900737L (sv)	1980-07-30
NL8000426A (nl)	1980-07-31
GB2041220B (en)	1983-07-27
SE7910354L (sv)	1980-07-30
DK316186A (da)	1986-07-03
DE3001454C2 (da)	1990-05-10
JPS55102512A (en)	1980-08-05
NL190693C (nl)	1994-07-01
NO153520C (no)	1986-04-09
JPH0140013B2 (da)	1989-08-24
FR2447191A1 (fr)	1980-08-22
BE881351A (fr)	1980-05-16
DK160739B (da)	1991-04-15
NO153520B (no)	1985-12-30
DK160740C (da)	1991-09-30
GB2041220A (en)	1980-09-10
NL190693B (nl)	1994-02-01
DK33580A (da)	1980-07-30

Publication	Publication Date	Title
SE431821B (sv)	1984-03-05	Lagringsstabilt, prostaglandininnehallande medicinskt preparat
KR940011241B1 (ko)	1994-12-03	고점성 하이드로겔 또는 현탁액 형성용 약학적 제제의 제조방법
TWI234465B (en)	2005-06-21	Stable complexes of poorly soluble compounds
Valenta	2005	The use of mucoadhesive polymers in vaginal delivery
CA2247191C (en)	2005-01-04	Powdery composition for nasal administration
KR20120102585A (ko)	2012-09-18	신속 용해 고체 투약 제형
Mishra et al.	2011	Development and evaluation of mucoadhesive buccal patches of flurbiprofen
JP2002514589A (ja)	2002-05-21	動物組織への生物活性剤の投与のための粘膜付着性組成物
PT85819B (pt)	1990-08-31	Processo para a preparacao de membranas de revestimento e de composicoes farmaceuticas obtidas a partir delas
WO2011159626A1 (en)	2011-12-22	Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
EP0468392A1 (en)	1992-01-29	Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained
TW201422254A (zh)	2014-06-16	用於速釋及延釋的組成物
Tuğcu-Demiröz	2017	Vaginal delivery of benzydamine hydrochloride through liposomes dispersed in mucoadhesive gels
EP3250184B1 (en)	2024-12-18	Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
EP0089768A1 (en)	1983-09-28	Compositions containing prostaglandins
Ofokansi et al.	2007	Formulation and evaluation of microspheres based on gelatin-mucin admixtures for the rectal delivery of cefuroxime sodium
JP2001002589A (ja)	2001-01-09	穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
EP0391852A2 (en)	1990-10-10	Pharmaceutical compositions
CN106560175A (zh)	2017-04-12	一种薄荷脑-樟脑低共熔物纳米乳原位凝胶制剂
KR101850350B1 (ko)	2018-04-19	경구용 서방출 젤리제제 및 이의 제조방법
WO2022065404A1 (ja)	2022-03-31	耳内投与用の医薬組成物
JP2003534054A (ja)	2003-11-18	シリコーン製剤の滅菌方法
CN110505871A (zh)	2019-11-26	用于药物吸收的高负载快速崩解膜
NZ232797A (en)	1991-07-26	Preparation of hydrogels and xerogels comprising acrylic copolymer and pharamceutical active agent using aqueous alkali to effect gelation
JPS63222121A (ja)	1988-09-16	徐放性ゲル製剤

Legal Events

Date	Code	Title	Description
1994-06-20	SPCF	Application for supplementary protection certificate filed	Free format text: 7900737
1995-01-31	NAL	Patent in force	Ref document number: 7900737-3 Format of ref document f/p: F
1996-05-13	SPCG	Supplementary protection certificate granted	Free format text: 9490102, 861107, EXPIRES: 20001128
1999-03-29	NUG	Patent has lapsed	Ref document number: 7900737-3 Format of ref document f/p: F